Brief Review of Newer Antiglycemic Agents as Options in the Treatment of Diabetic Kidney Disease
Open Access
- 11 May 2020
- journal article
- review article
- Published by Peertechz Publications Private Limited in Global Journal of Obesity, Diabetes and Metabolic Syndrome
- Vol. 7 (2), 009-011
- https://doi.org/10.17352/2455-8583.000041
Abstract
Diabetes remains the leading cause of chronic kidney disease and with its increased prevalence the risk for Diabetic Kidney Disease (DKD) continues to rise and has a significant impact on diabetes morbidity and mortality as well as health care resources.Keywords
This publication has 29 references indexed in Scilit:
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesThe New England Journal of Medicine, 2016
- Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairmentDiabetologia, 2016
- Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical TrialDiabetes Care, 2015
- Cardiovascular Complications of Diabetic Kidney DiseaseAdvances in Chronic Kidney Disease, 2014
- Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal DysfunctionDiabetes Care, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2013
- Efficacy of alogliptin, a dipeptidyl peptidase‐4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetesDiabetes/Metabolism Research and Reviews, 2013
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes, Obesity and Metabolism, 2013
- Kidney Disease and Increased Mortality Risk in Type 2 DiabetesJournal of the American Society of Nephrology, 2013
- Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetesInternational Journal of Clinical Practice, 2012